Introducing ropivacaine into a department’s epidural analgesic practice. Improving acute pain service practice
| Autor: | T.J. Towell, M. Jones, D.J.R. Duthie, R. Wyatt, S. Maric |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
Leadership and Management Nausea Analgesic Fentanyl medicine Humans Ropivacaine Anesthetics Local Adverse effect Acute pain Aged Pain Measurement Bupivacaine Pain Postoperative business.industry Analgesia Patient-Controlled Middle Aged Amides United Kingdom Surgery Analgesia Epidural Anesthesia Vomiting medicine.symptom business Adjuvants Anesthesia medicine.drug |
| Zdroj: | British Journal of Clinical Governance. 5:217-221 |
| ISSN: | 1466-4100 |
| DOI: | 10.1108/14664100010361836 |
| Popis: | The results of introducing a new licensed local anaesthetic drug, ropivacaine, into routine practice were evaluated by measuring the efficacy and adverse effects of patient controlled epidural analgesia (PCEA), using ropivacaine 2mg/ml (R), or the mixtures in current use: fentanyl 5 (μg/ml with bupivacaine 1mg/ml (BF5) and fentanyl 10 (μg/ml) with bupivacaine 1mg/ml (BF10). All patients were nursed on general wards after surgery. For two months, 102 consecutive patients were studied. Pain scores at rest were significantly better in the fentanyl and bupivacaine groups, (mean rank R: 35.5, BF5: 22.7, BF10: 26.9, Pp < 0.001), and pain on moving (p < 0.001). Nausea and vomiting was worse in the BF10 (p < 0.05). Older patients demanded less analgesia (p < 0.001). Postoperatively BF5 provided better pain relief with trends demonstrating fewer side‐effects and complications than BF10 or R. We now use fentanyl 5 (μg/ml and bupivacaine 1mg/ml as our standard epidural infusion mixture. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|